| This week's sponsor is FierceBiotech. | |  | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, May 7, 2019 Allergan Chairman and CEO Brent Saunders gets to keep both his titles, thanks to a shareholder vote that broke in his favor. But he answered critics Tuesday with a promise that Allergan's weighing all its options now—including a split—with a "sense of urgency." |
|
|
Top Stories Of The Week Friday, May 3, 2019 Interim data from a phase 1 study of Celgene and Bluebird Bio's CAR-T treatment for multiple myeloma, bb2121, showed median progression-free survival of about a year. But a high relapse rate could compound concerns about the durability of the treatment, which is a key asset in Bristol-Myers Squibb's $74 billion buyout of Celgene. Wednesday, May 8, 2019 AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate has hit the primary endpoint in a pivotal phase 2 trial, teeing the partners up to file for FDA approval in the first half of the fiscal year. Friday, May 3, 2019 Novo Nordisk has been fighting head-to-head with Eli Lilly for share in the GLP-1 diabetes market—and losing, as Lilly's weekly Trulicity stole scripts from Novo's daily Victoza. But now that Novo has its own weekly GLP-1 drug in Ozempic, the tide appears to be turning. Friday, May 3, 2019 Gilead tapped new CEO Daniel O’Day in part because of his cancer expertise, gained from years at top cancer drugmaker Roche. But he’s not planning to lead the company’s oncology ramp-up alone. Wednesday, May 8, 2019 As Philips transitions from a hardware manufacturer to an integrated service provider, Chief Innovation Officer Jeroen Tas describes the company's approach of using artificial intelligence and other technologies to help shepherd patients across the gap from consumer health to professional care and back again. Monday, May 6, 2019 Once rejected by the FDA, Pfizer's tafamidis is back and ready to disrupt a rare disease field only recently tapped by Alnylam and Ionis—and the Big Pharma's challenger boasts a much lower price tag than its rivals'. But to hit its blockbuster mark, Pfizer needs to spread awareness of the rare disease it treats. Monday, May 6, 2019 Lundbeck is set to pay $250 million (€223 million) upfront to buy Abide Therapeutics. The deal will give Lundbeck a phase 2a Tourette's syndrome program, a CNS drug discovery platform and a West Coast research hub. Wednesday, May 8, 2019 Merck & Co. has been experiencing a surging wave of Gardasil sales that it expects to ride for some time yet. To maintain the momentum, the drugmaker says it will spend $1 billion to expand production. Tuesday, May 7, 2019 Artificial intelligence in drug development is among the hottest buzzwords in biopharma right now, but often real progress from it is hampered by a lack of expertise and less than equal access to its latent potential. Resources Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. |
|
